In June 2021, the FDA approved Wegovy (semaglutide) for weight management in overweight or obese adults with co-occurring health issues
effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Additionally, this diabetes drug has been associated with weight loss, leading some healthcare providers to prescribe it off-label for this purpose, further increasing its popularity and usage
Without controlled testing, attributing positive or negative outcomes to the vendor specifically versus other variables remains difficult
Support, training and mentorship opportunities for early career scientists, clinicians, and students
[DOI] [PubMed] [Google Scholar] 13.Zaki H, Sabharwal A, Kramer J, Aguirre A